Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors

Lobefaro, Riccardo; Rota, Simone; Porcu, Luca; Brunelli, Cinzia; Alfieri, Sara; Zito, Emanuela; Taglialatela, Ida; Ambrosini, Margherita; Spagnoletti, Andrea; Zimatore, Matteo; Fatuzzo, G.; Lavecchia, Filomena; Borreani, Claudia; Apolone, Giovanni; Braud, Filippo de; Platania, Marco

doi:10.1016/j.esmoop.2022.100457

Cited by 18 publications

(14 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the actual incidence of RC48‐ADC treatment‐related anemia might be lower than observed in this study. Furthermore, patients with poor ECOG PS, anemia, distress, pain, and those undergoing oncological treatment were found to be at significantly higher risk for cancer‐related fatigue 39 . In alignment with the findings of previous studies, the incidence of TRAEs was higher in patients who received combination therapy compared to those who received RC48 monotherapy.…”

Section: Discussionsupporting

confidence: 81%

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Xu,

Zhang,

Zhang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

IntroductionPrevious RC48 (Disitamab Vedotin) studies established that the safety and efficacy of RC48‐antibody–drug conjugate (ADC), either alone or combined with toripalimab, for metastatic urothelial carcinoma (mUC) patients exhibiting human epidermal growth factor receptor 2 (HER2)‐positive or even HER2‐negative status after standard chemotherapy failure.MethodsWith locally advanced or metastatic urothelial carcinoma (la/mUC), patients who received RC48‐ADC monotherapy or a combination with programmed cell death protein 1 (PD‐1) inhibitors between August 2021 and October 2022 were enrolled in this retrospective observational study to evaluate the real‐world antitumor effectiveness and safety.ResultsAmong the 38 enrolled patients (29 males; median age 67.5 years [38–93]), 8 received RC48‐ADC monotherapy, while 30 received combination therapy. Initially, 63.2% (24/38) of the patients had received ≥1 line of prior treatment, and 63.2% (24/38) had visceral metastasis. UC of the bladder represented the majority type in 68.4% (26/38) of cases. By the data cutoff in March 2023, the overall objective response rate (ORR) was 63.2% (95% CI, 47.1%–79.2%), with a disease control rate (DCR) of 89.5% (95% CI, 79.3%–99.7%). Median follow‐up time was 10.6 months. The median progression‐free survival (PFS) was 8.2 months (95% CI, 5.9–10.5), with a 6‐month PFS rate of 63.2% and a 12‐month PFS rate of 34.1%. Median overall survival (OS) was not reached, with a 12‐month OS rate of 76.7%. The median duration of response was 7.3 months (95% CI, 4.6–10.0) among 24 patients evaluated as partial response (PR). The most common treatment‐related adverse events (TRAEs) included anemia (71.1%), anorexia (57.9%), asthenia (52.6%), hypoesthesia (52.6%), bone marrow suppression (47.4%), alopecia (47.4%), nausea (44.7%), proteinuria (36.8%), vomiting (34.2%), and hypoalbuminemia (31.6%). No patient experienced TRAEs of Grade ≥3. One patient had an immune‐related adverse event (irAE) of rash related to toripalimab.ConclusionsBoth as monotherapy and in combination with PD‐1 inhibitors, RC48‐ADC exhibits promising effectiveness and manageable safety profile for mUC patients in real‐world settings.

show abstract

Section: Discussionsupporting

confidence: 81%

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Xu,

Zhang,

Zhang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Once the mitochondria are damaged, the energy supply is reduced, which results in fatigue [5,6,8]. However, the prevalence of the current study was much higher than studies which have been conducted in South Korea, 67.2% [50], Lebanon, 46.3% [51], Italy, 43.5%, [52], and Netherlands, 48% [53]. This discrepancy might be due to the difference in study population, sample size, tool, and eligibility criteria [6,54,55].…”

Section: Plos Onementioning

confidence: 55%

Fatigue and associated factors among adult cancer patients receiving cancer treatment at oncology unit in Amhara region, Ethiopia

et al. 2023

View full text Add to dashboard Cite

Introduction Fatigue is one of the most commonly and frequently reported symptoms by cancer patients. The cause of fatigue is multifactorial in origin, and its impact varies in range from affecting patients’ daily social life, and physical, mental, economic, and social well-being to becoming a threat to their quality of life. Therefore every cancer patient needs to be screened for fatigue and considered as one of the vital signs. Objective To assess the prevalence of fatigue and associated factors among adult cancer patients, receiving cancer treatment at the oncology unit in Amhara region, Ethiopia, 2022. Method Institutional-based, cross-sectional study was conducted among adult cancer patients receiving cancer treatment from May 9th–June 8th, 2022. A stratified random sampling technique was used to select study participants. Data were entered into Epi data version 4.6 and then exported to the SPSS statistical package version 23 for further analysis. Both bivariable and multivariable logistic regression analyses were carried out. P-values <0.05 in multivariable logistic regression were considered statistically significant. Results The prevalence of cancer-related fatigue was 77.3% at 95% CI (73.1–81.1) with nonresponse rate of 1.97% (9). Poor social support (AOR = 3.62; 95% CI: 1.53–8.60), anxiety (AOR = 3.13; 95% CI: 1.54–6.36), physical inactivity (AOR = 3.67; 95% CI: 1.74–7.54), underweight (AOR = 2.03; 95% CI: 1.05–3.90), anemia (AOR = 2.01; 95% CI: 1.04–3.90), surgery as a treatment modality (AOR = 0.21; 95% CI: 0.06–0.78), combination therapy (AOR = 3.56; 95% CI: 1.68–7.54), treatment less than 3 cycle (AOR = 4.43; 95% CI: 1.53–12.80), and treatment 3–5 cycle (AOR = 3.55; 95% CI: 1.38–9.09) were significantly associated factors with cancer related fatigue. Conclusion Psychosocial assessment and intervention, nutritional support, early intervention of anemia, and promoting exercise are the key elements to minimizing fatigue among cancer patients.

show abstract

“…The correlation between CRF and anxiety/depression is undeniable. However, the association between CRF and depression seems to receive more attention than that between CRF and anxiety ( 26 – 28 ). A systematic review of 59 studies showed that the correlation between anxiety (0.46) and CRF is weaker than that between depression and CRF (0.56) ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

Bibliometric and visualization analyses of cancer-related fatigue research published worldwide from 2001 to 2023

Li,

Wang,

Feng

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveCancer seriously endangers human health and represents a global public health issue. Cancer-related fatigue (CRF) is a distressing and persistent sense of exhaustion caused by cancer or cancer treatment, widely prevalent among cancer patients. This study aims to summarize emerging trends and provide directions for future research of CRF through bibliometric and visualization analyses.MethodsA systematic search in the Web of Science Core Collection database from 2001-01-01 to 2023-05-18 were conducted. Only reviews and articles written in English were considered. CiteSpace and the R were used for bibliometric and visualization analyses.ResultsThe analysis revealed that 2,566 studies on CRF have been published by 1,041 institutions in 70 countries so far. The number of articles published and cited annually have been steadily increasing. Eduardo Bruera published the most articles, and Julienne E Bower is the most co-cited author. The University of Texas System is the leading institution in cancer-related fatigue research. The United States and China have the largest number of publications. Supportive Care in Cancer published the most articles, and Journal of Clinical Oncology is the most co-cited journal. “Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis”, authored by Mustian KM et al. and published in JAMA Oncology was the most co-cited document. Keyword analysis indicated that research focus had shifted from “epoetin alpha” and “anemia” to “risk factors”, “systematic review”, “acupuncture”, “anxiety”, “traditional Chinese medicine” and “guidelines”.ConclusionIn conclusion, this analysis provides comprehensive research trends and knowledge network maps of CRF. Clinical physicians should concurrently focus on the anemia, insomnia, anxiety, and depression status of patients when assessing or managing CRF. Improvements in related risk factors also contribute to alleviating fatigue. Furthermore, it is essential to pay attention to authoritative CRF guidelines. Acupuncture and traditional Chinese medicine also have therapeutic potential, which merits further investigation. Researchers should draw attention to the crucial roles of inflammation, hypoxia, and mitochondrial dysfunction, which could be the frontiers.

show abstract

Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors

Cited by 18 publications

References 77 publications

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Fatigue and associated factors among adult cancer patients receiving cancer treatment at oncology unit in Amhara region, Ethiopia

Bibliometric and visualization analyses of cancer-related fatigue research published worldwide from 2001 to 2023

Contact Info

Product

Resources

About